Drug delivery systems
View Patent ↗Matrix controlled diffusion drug delivery systems based on one or more silicone-containing monomers of the general formula: wherein x, y, m, m′, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Z and Z′ are as defined herein are provided, wherein the matrix controlled diffusion drug delivery systems are sized and configured for back of the eye delivery.
1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a polymerization product of a monomeric mixture comprising one or more silicone-containing monomers of the general formula:
wherein x and y are independently integers from 0 to about 300; m and m′ are independently integers from 1 to about 6, R is independently a straight or branched, substituted or unsubstituted, C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, an ether or polyether containing group or a C 1 -C 30 alkylamide group, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently hydrogen, a straight or branched C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a C 1 -C 20 ester group, an alkyl ether, cycloalkyl ether, cycloalkylalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether or polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclolalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, fluorine, a vinyl group, a C 5 -C 30 fluoroaryl group, or a hydroxyl group; X is independently a straight or branched C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 1 -C 30 alkoxy group, an ether, polyether, sulfide, or amino containing group and Z and Z′ are independently a polymerizable ethylenically unsaturated organic radical, wherein the matrix controlled diffusion drug delivery system is sized and configured for back of the eye delivery.
2. The matrix controlled diffusion drug delivery system of claim 1 , wherein x is 2 to about 100, y is 2 to about 100, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently a straight or branched C 1 -C 30 alkyl group, and Z and Z′ are selected from an ester or amide of acrylic or methacrylic acid.
3. The matrix controlled diffusion drug delivery system of claim 1 , wherein x is 2 to about 100, y is 2 to about 100, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently a straight or branched C 1 -C 6 alkyl group X is a bond or an ether or polyether containing group, and Z and Z′ are independently an ester or amide of acrylic or methacrylic acid.
4. The matrix controlled diffusion drug delivery system of claim 1 , wherein x is 2 to about 100, y is 2 to about 100, R is independently a straight or branched C 1 -C 30 fluoroalkyl group, an alkyl ether or polyether group or a straight or branched C 1 -C 30 alkylamide group, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently a straight or branched C 1 -C 6 alkyl group, X is independently a bond or one or more C 1 -C 30 alkyl ether groups or polyether groups and Z and Z′ are independently an ester or amide of acrylic or methacrylic acid.
5. The matrix controlled diffusion drug delivery system of claim 1 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anti-glaucoma agent, anti-cataract agent, anti-diabetic retinopathy agent, thiol cross-linking agent, anti-cancer agent, immune modulator agent, anti-clotting agent, anti-tissue damage agent, anti-inflammatory agent, anti-fibrous agent, non-steroidal anti-inflammatory agent, antibiotic, anti-pathogen agent, piperazine derivative, cycloplegic agent, miotic agent, mydriatic agent and mixtures thereof.
6. The matrix controlled diffusion drug delivery system of claim 1 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anticholinergic, anticoagulant, antifibrinolytic, antihistamine, antimalarial, antitoxin, chelating agent, hormone, immunosuppressive, thrombolytic, vitamin, protein, salt, desensitizer, prostaglandin, amino acid, metabolite, antiallergenic and mixtures thereof.
7. The matrix controlled diffusion drug delivery system of claim 1 , wherein the monomeric mixture comprises one or more other monomers or prepolymers.
8. The matrix controlled diffusion drug delivery system of claim 7 , wherein the one or more monomers are selected from the group consisting of methyl methacrylate, 2-ethylhexyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, dimethyl itaconate, trifluoromethyl methacrylate, hexafluoroisopropyl methacrylate, bis(hexafluoroisopropyl) methacrylate, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, acrylic acid, itaconic acid, acrylic anhydride, methacrylic anhydride, maleic anhydride, itaconic anhydride, glycerol methacrylate, hydroxypropyl methacrylate, N,N-dimethylacrylamide, acrylamide, N-methylacrylamide, N-vinylpyrrolidione, N-isopropylacrylamide, hydroxybutyl methacrylate and mixtures thereof.
9. The matrix controlled diffusion drug delivery system of claim 1 , in a form of a solution, suspension, solution/suspension, microsphere or nanosphere.
10. The matrix controlled diffusion drug delivery system of claim 1 , in a form of a semi-solid or solid article suitable for ocular implant.